Clinical Trial Update: PALISADE Follow-on Study (ARC004) [Phase 3]

View source ↗

Summary

Phase 3 follow-on study (ARC004) for peanut allergy completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Palforzia (defatted powder of Arachis hypogaea L., semen (peanuts))

Snippet

Sponsor: Aimmune Therapeutics, Inc. | Conditions: Peanut Allergy | Phase 3 | Status: COMPLETED | Results posted: 2021-12-15